Download the high-resolution version of the image. (104 KB)
Download the high-resolution version of the image. (112 KB)
Download the high-resolution version of the image. (963 KB) |
Download the high-resolution version of the image. (142 KB)
Download the high-resolution version of the image. (178 KB)
Download the high-resolution version of the image. (62 KB)
Watch where you jump in for a swim or where your bath water comes
from, especially if you live in Africa, Asia or South America. Snails
that live in tropical freshwater in these locations are intermediaries
between disease-causing parasitic worms and humans.
People in
developing countries who don't have access to clean water and good
sanitation facilities are often exposed to the infected snails. Then
they're left open to the parasitic worms.
The worms' infectious
larvae emerge from the snails, cruise in shallow water, easily penetrate
human skin and mature in internal organs.
The result is
schistosomiasis, the second most socioeconomically devastating disease
after malaria. As of 2009, 74 developing nations had identified
significant rates of schistosomiasis in human populations.
There
has been much debate about how best to prevent the disease, says Charles
King, a physician and researcher at Case Western Reserve University in
Cleveland, Ohio. "Beyond that," he asks, "how long should treatment last
once someone has schistosomiasis?"
"Current guidelines focus on
suppressing the disease's effects by limiting the infection during
childhood," says King. "But that may not be enough to cure it or to
prevent re-infection, leaving children still at risk for stunted growth
and anemia."
King and colleagues recently published results of a study of long-term treatment of schistosomiasis in the journal PLOS Neglected Tropical Diseases.
The
team's work is funded by the National Science Foundation (NSF)-National
Institutes of Health (NIH) Evolution and Ecology of Infectious Diseases
(EEID) program.
At NSF, the EEID program is supported by the
Directorate for Biological Sciences and Directorate for Geosciences. At
NIH, it's supported through the Fogarty International Center.
Schistosomiasis is usually treated with a single dose of the oral drug praziquantel.
World
Health Organization (WHO) guidelines set forth in 2006 recommend that
when a village reports that more than 50 percent of its children have
parasite eggs in their urine or stool--a clear sign of
schistosomiasis--everyone in the village should receive treatment.
When
10 to 50 percent of children are affected, say the guidelines, only
school-age children should be treated--every two years. With less than
10 percent, mass treatment is not suggested.
But because of the
long-term health effects of schistosomiasis, says King, "we now think
it's better to provide regular yearly treatment."
He and
scientists Xiaoxia Wang, David Gurarie and Peter Mungai of Case Western
Reserve University; Eric Muchiri of the Ministry of Public Health and
Sanitation in Nairobi, Kenya; and Uriel Kitron of Emory University in
Atlanta, Georgia, used data collected in 10 villages in southeastern
Kenya to run advanced models of village-level schistosomiasis
transmission.
They scored the number of years each of the 10
villages would be projected to remain below a 10 percent infection level
during a simulated 10-to-20-year treatment program.
All
strategies that included an initial four annual treatments reduced
community prevalence of the disease to less than 10 percent. Programs
with gaps in treatment, however, didn't reach this objective in half the
villages.
At typical levels of treatment, the researchers found,
current WHO recommendations likely could not achieve full suppression of
schistosomiasis.
"With more aggressive annual intervention that
lasts at least four years," says King, "some communities might be able
to continue without further treatment for 8 to 10 years.
"But in
higher-risk villages, repeated annual treatment may be necessary for an
indefinite period--until the eco-social factors that foster the disease
[such as poor wastewater treatment] are removed."
In high-risk
places, ongoing surveillance for the disease and annual drug treatment,
the scientists say, need to become the mainstays of control.
In short, these villages require what they call "re-worming after de-worming."
But what happens if townspeople move to a more arid location, one with less freshwater and fewer snails?
In
drier landscapes, schistosomiasis is a rare event that happens only
during floods. Response to treatment therefore may be much better.
Unless or until another flood occurs.
Although drier locales carry
less risk for the disease, they're by no means free and clear. Even in
arid locations, people would likely need to be treated more than once to
get rid of the parasites.
"This research demonstrates the value
of understanding where disease-causing organisms are in the
environment," says Sam Scheiner, NSF program officer for EEID.
"Such knowledge can reduce human diseases much more effectively and at a lower cost than simply focusing on treatment."
The best goal, says King, is complete eradication of schistosomiasis.
To
achieve that, scientists need to determine what makes a "wormy
village," how often therapy is needed to prevent disease in such
locations--and what can be done to change the environment such that a
high-risk village becomes a low-risk one.
Related Websites
NSF Special Report: Ecology and Evolution of Infectious Diseases:
NSF Special Report: Ecology and Evolution of Infectious Diseases:
http://www.nsf.gov/news/special_reports/ecoinf/index.jsp
NSF News Release: Controlling the Spread of Diseases Among Humans, Other Animals and the Environment:
NSF News Release: Controlling the Spread of Diseases Among Humans, Other Animals and the Environment:
The National Science Foundation (NSF).
Guillermo Gonzalo Sánchez Achutegui
ayabaca@gmail.com
ayabaca@hotmail.com
ayabaca@yahoo.com
Inscríbete en el Foro del blog y participa : A Vuelo De Un Quinde - El Foro!
No hay comentarios:
Publicar un comentario